% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zheng:167590,
      author       = {G. Zheng$^*$ and J. Sundquist and K. Sundquist and J. Ji},
      title        = {{B}eta-blockers use and risk of breast cancer in women with
                      hypertension.},
      journal      = {Cancer epidemiology, biomarkers $\&$ prevention},
      volume       = {30},
      number       = {5},
      issn         = {1538-7755},
      address      = {Philadelphia, Pa.},
      publisher    = {AACR},
      reportid     = {DKFZ-2021-00450},
      pages        = {965-973},
      year         = {2021},
      note         = {#EA:C020# / 30(5):965-973},
      abstract     = {The risk of breast cancer among hypertensive patients who
                      use beta-blockers has attracted attention. However, the
                      evidence is inconsistent and investigation of the
                      dose-specific associations for subtypes of beta-blockers are
                      limited.By incorporating Swedish national registers, breast
                      cancer risk was estimated in women with hypertension who
                      used nonselective beta-blockers and beta-1 selective
                      blockers compared with propensity score-matched non-users.
                      The cumulative defined daily dose was used to study the
                      dose-response association. Test of interaction between
                      beta-blocker use and other antihypertensive medications was
                      performed.Hypertensive patients taking beta-1 selective
                      blockers (metoprolol, atenolol, bisoprolol) had an increased
                      risk of breast cancer with a hazard ratio (HR) and $95\%$
                      confidence interval (CI) of 2.39 (1.95-2.94), 2.31
                      (1.46-3.64), and 3.02 (2.09-4.36), respectively. All of the
                      observed associations were dose-dependent (P trend <0.0001).
                      No significant association was found for the nonselective
                      beta-blocker (propranolol) except that among users of agents
                      acting on the renin-angiotensin system, those who used
                      propranolol had increased breast cancer risk. Modification
                      of agents acting on the renin-angiotensin system on breast
                      cancer risk was also observed for atenolol.The increased
                      risk of breast cancer associates with the use of beta-1
                      selective blockers in a dose-response manner.Breast cancer
                      surveillance is recommended for hypertensive female patients
                      using beta-1 selective blockers.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33619022},
      doi          = {10.1158/1055-9965.EPI-20-1599},
      url          = {https://inrepo02.dkfz.de/record/167590},
}